Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece

Cost Effectiveness and Resource Allocation

Volumn 12, Issue 1, 2014, Pages

  Kourlaba, Georgia ^a   Maniadakis, Nikos ^b   Andrikopoulos, George ^c   Vardas, Panos ^d  

^a Clinical Epidemiology and Outcomes Research (CLEO)   (Greece)

^b NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^c HENRY DUNANT HOSPITAL   (Greece)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Cost effectiveness; Cost utility; Vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; RIVAROXABAN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; EMBOLISM; GREECE; HEALTH CARE QUALITY; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; QUALITY ADJUSTED LIFE YEAR; AGED; COST; DISEASE COURSE; MONITORING; OUTCOME ASSESSMENT; PROBABILITY;

EID: 84896733520     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-12-5     Document Type: Article

References (45)

1. Rich MW. Epidemiology of atrial fibrillation. J Interv Card Electrophysiol 2009, 25:3-8. 10.1007/s10840-008-9337-8, 19160031.
2. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006, 119:448. e441-419.
3. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007, 28:2803-2817. 10.1093/eurheartj/ehm358, 17897924.
4. Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 2011, 13:1375-1385. 10.1093/europace/eur194, 21757483.
5. Jeantet M, Losay J, Cassinat G, Andral J, Guize L, de Pouvourville G. Paroxysmal atrial fibrillation in community medicine: management intentions and cost estimates. Arch Mal Coeur Vaiss 2001, 94:1103-1109.
6. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006, 9:348-356. 10.1111/j.1524-4733.2006.00124.x, 16961553.
7. Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004, 90:286-292. 10.1136/hrt.2002.008748, 1768125, 14966048.
8. Vardas P, Vasilikos V, Livanis E. Pharmaceutical management of arrythmias. Guidelines of National Medicines Agency 2011, http://www.eof.gr (accessed 30.01.2012).
9. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429.
10. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson SB, Ellenbogen KA, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann LS, Jacobs AK, Anderson JL, Albert N, Hochman JS. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011, 2011(57):223-242.
11. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870. 10.1001/jama.285.22.2864, 11401607.
12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867. 10.7326/0003-4819-146-12-200706190-00007, 17577005.
13. European Medicines Agency Xarelto. Summary of Product Characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000944/WC500057109.pdf. Date Accessed Oct 2013, European Medicines Agency.
14. ROCKET AF Study Investigators Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010, 159:340-347. e341, ROCKET AF Study Investigators.
15. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891. 10.1056/NEJMoa1009638, 21830957, ROCKET AF Investigators.
16. Maniadakis N, Kaitelidou D, Siskou O, Spinthouri M, Liaropoulos L, Fragoulakis B, Hatzikou M, Alexopoulosi D. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. Hell J Cardiol 2005, 46:212-221.
17. National Institute for Health and Clinical Excellence Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Accessed Feb 2013 [http://www.nice.org.uk/nicemedia/live/13746/59295/59295.pdf], National Institute for Health and Clinical Excellence.
18. Testa L, Agnifili M, Latini RA, Mattioli R, Lanotte S, De Marco F, Oreglia J, Latib A, Pizzocri S, Laudisa ML, Brambilla N, Bedogni F. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM 2012, 105:949-957. 10.1093/qjmed/hcs114, 22771555.
19. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005, 36:1115-1119. 10.1161/01.STR.0000166053.83476.4a, 15879330.
20. Eckman MH, Levine HJ, Pauker SG. Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease. Chest 1992, 102:538S-549S. 10.1378/chest.102.4_Supplement.538S, 1395834.
21. Hoit BD, Gilpin EA, Henning H, Maisel AA, Dittrich H, Carlisle J, Ross J. Myocardial infarction in young patients: an analysis by age subsets. Circulation 1986, 74:712-721. 10.1161/01.CIR.74.4.712, 3757185.
22. Kleintjens J, Li X, Simoens S, Thijs V, Goethals M, Rietzschel ER, Asukai Y, Saka O, Evers T, Faes P, Vansieleghem S, De Ruyck M. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the belgian healthcare setting. Pharmacoeconomics 2013, 31(10):909-918. 10.1007/s40273-013-0087-9, 3824571, 24030788.
23. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012, 110:845-851. 10.1016/j.amjcard.2012.05.011, 22651881.
24. Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006, 24:1021-1033. 10.2165/00019053-200624100-00009, 17002484.
25. Robinson A, Thomson R, Parkin D, Sudlow M, Eccles M. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J Health Serv Res Policy 2001, 6:92-98. 10.1258/1355819011927288, 11357250.
26. Hallan S, Asberg A, Indredavik B, Wideroe TE. Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes. J Intern Med 1999, 246:309-316. 10.1046/j.1365-2796.1999.00531.x, 10475999.
27. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc 1997, 4:49-56. 10.1136/jamia.1997.0040049, 61198, 8988474.
28. Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke 2006, 37:193-198. 10.1161/01.STR.0000196990.69412.fb, 16339458.
29. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. The Centre for Health Economics. University of York. Book UK population norms for EQ-5D. The Centre for Health Economics 1999, York: The University of York.
30. Lamotte M, Annemans L, Bridgewater B, Kendall S, Siebert M. A health economic evaluation of concomitant surgical ablation for atrial fibrillation. Eur J Cardiothorac Surg 2007, 32:702-710. 10.1016/j.ejcts.2007.07.027, 17768060.
31. Berg J, Lindgren P, Nieuwlaat R, Bouin O, Crijns H. Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res 2010, 19:381-390. 10.1007/s11136-010-9591-y, 20108048.
32. Lacey EA, Walters SJ. Continuing inequality: gender and social class influences on self perceived health after a heart attack. J Epidemiol Community Health 2003, 57:622-627. 10.1136/jech.57.8.622, 1732552, 12883071.
33. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001, 135:870-883. 10.7326/0003-4819-135-10-200111200-00007, 11712877.
34. Greek Ministry of Health Diagnostic Related Groups 2012, [http://www.yyka.gov.gr/articles/health/domes-kai-draseis-gia-thn-ygeia/kwdikopoihseis/709-kleista-enopoihmena-noshlia-1], Greek Ministry of Health.
35. Maniadakis N, Kourlaba G, Cokkinos D, Angeli A, Kyriopoulos J. The economic burden of atherothrombosis in Greece: results from the THESIS study. Eur J Health Econ 2013, 14(4):655-665. 10.1007/s10198-012-0412-9, 22777727.
36. Greek Ministry of Health Drug Price Bulletin Accessed at August 2013 [http://www.yyka.gov.gr/], Greek Ministry of Health.
37. Greek Ministry of Health Positive Drug List, Availabe at: FEK1184/B/15.5.2013 2013, Accessed at August 2013. http://www.sfee.gr/files/story/305.pdf, Greek Ministry of Health.
38. Maniadakis N, Fragoulakis V, Pectasides D, Fountzilas G. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr Med Res Opin 2009, 25:797-805. 10.1185/03007990902719117, 19215190.
39. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 2004, 7:518-528. 10.1111/j.1524-4733.2004.75003.x, 15367247.
40. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004, 13:437-452. 10.1002/hec.864, 15127424.
41. World Health Organization WHO Commission on Macroeconomics and Health: Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Book WHO Commission on Macroeconomics and Health: Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health 2001, World Health Organization.
42. Pattacini C, Manotti C, Pini M, Quintavalla R, Dettori AG. A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol). Thromb Haemost 1994, 71:188-191.
43. Barcellona D, Vannini ML, Fenu L, Balestrieri C, Marongiu F. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?. Thromb Haemost 1998, 80:899-902.
44. Morin S, Bodin L, Loriot MA, Thijssen HH, Robert A, Strabach S, Verstuyft C, Tregouet DA, Dubert L, Laurent-Puig P, Funck-Brentano C, Jaillon P, Beaune PH, Becquemont L. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther 2004, 75:403-414. 10.1016/j.clpt.2004.01.008, 15116053.
45. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005, 44:1227-1246. 10.2165/00003088-200544120-00003, 16372822.